Low-Dose Weekly vs High-Dose Cisplatin

ConditionLocally Advanced Head and Neck Squamous Cell Carcinoma

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

About this trial

This study is a prospective open-label randomized clinical trial. Following informed consent eligible LASCCHN patients (n=100) planned for CRT will be stratified by tumor p16 status and then randomized in a 1:1 fashion to either concurrent HD cisplatin or concurrent weekly LD cisplatin.

Eligibility criteria

Qualifiers

Age 18 or older

Willing and able to provide written informed consent

Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Histologically or cytologically confirmed squamous cell carcinoma

Disqualifiers

Serious medical comorbidities or other contraindications to radiotherapy and/or chemotherapy.

Prior history of head and neck cancer within 5 years.

Nasopharyngeal primary confirmed or suspected.

Severe hearing loss as determined clinically Pre-existing use of hearing aids.

Trial design

Treatments tested in this trial

High-Dose Cisplatin
Low-Dose Cisplatin
Radiotherapy

Treatment groups

100 Participants

are divided into 2 treatment groups

Sponsors and collaborators

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Lead sponsor

Source ClinicalTrials.gov